The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for the next decade.
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback